CEL-SCI Corporation (CVM.A)

CVM.A on American Stock Exchange

1.11USD
18 Dec 2009
Price Change (% chg)

$0.04 (+3.74%)
Prev Close
$1.07
Open
$1.06
Day's High
$1.11
Day's Low
$1.06
Volume
134,100
Avg. Vol
2,410,422
52-wk High
$2.10
52-wk Low
$0.14

CVM.A

Chart for CVM.A

About

CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and... (more)

Buy/Sell

No analyst recommendations are available for CVM.A.
» Full Recommendation

Overall

Beta: 2.28
Market Cap (Mil.): $160.02
Shares Outstanding (Mil.): 149.55
Annual Dividend: 0.00
Yield (%): NA

Financials

  CVM.A Industry Sector
P/E (TTM): -- 11.78 4.61
EPS (TTM): -32.09 -- --
ROI: -85.78 1.35 2.83
ROE: -107.73 2.17 3.59
view overview for:

Latest News about CVM.A

CEL-SCI files for $30 million stock, warrant shelf

WASHINGTON, July 12 (Reuters) - CEL-SCI Corp , which develops drugs for cancer and infectious diseases, filed with U.S. regulators on Thursday to periodically sell up to $30 million in common stock and warrants.

12 Jul 2007

CEL-SCI's cancer drug gets orphan status

June 12 (Reuters) - CEL-SCI Corp. said the U.S. Food and Drug Administration granted an orphan drug status to its cancer drug, Multikine.

12 Jun 2007
» More CVM.A News

Competitors

  Price Change
IDM Pharma Inc. (IDMI.OQ) -- --
Neoprobe Corporation (NEOP.OB) $1.12 0.00
Orchestra Therapeutics, Inc. (OCHT.PK) $0.05 0.00

  Earnings  vs    Estimates

No consensus analysis data available.
view overview for: